Extended-release injection vs sublingual buprenorphine for opioid use disorder with fentanyl use
El fentanilo ha exacerbado el trastorno por consumo de opiáceos (TCO) y la epidemia de sobredosis de opiáceos. Los datos sobre la eficacia de los medicamentos para el trastorno por uso de opiáceos en pacientes que consumen fentanilo son limitados. El objetivo de esta investigación es evaluar la efic...
Збережено в:
| Автор: | |
|---|---|
| Інші автори: | |
| Формат: | Книга |
| Мова: | Іспанська Англійська |
| Предмети: | |
| Онлайн доступ: | Enlace web Path |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
Схожі ресурси: Extended-release injection vs sublingual buprenorphine for opioid use disorder with fentanyl use
- Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
- OPIOID ADDICTS AT ADMISSION VS. SLOW-RELEASE ORAL MORPHINE, METHADONE, AND SUBLINGUAL BUPRENORPHINE MAINTENANCE TREATMENT PARTICIPANTS
- TRENDS IN THE USE AND ABUSE OF BRANDED AND GENERIC EXTENDED RELEASE OXYCODONOE AND FENTANYL PRODUCTS IN THE UNITED STATES
- Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone
- Tinkering with care: Implementing extended-release buprenorphine depot treatment for opioid dependence
- Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness